News & Analysis as of

Counterfeit Drugs Intellectual Property Protection

McDonnell Boehnen Hulbert & Berghoff LLP

U.S. Trade Representative Releases 2023 Special 301 Report

In April, Ambassador Katherine Tai, U.S. Trade Representative (USTR), issued the 2024 Special 301 Report.  In a press release, the USTR stated that "[m]any of the issues highlighted in the Special 301 Report demand...more

Dechert LLP

UK Life Sciences and Healthcare Newsletter: Counterfeit Medicines: A Growing Threat to Consumers and Pharmaceutical Companies

Dechert LLP on

The European Union Intellectual Property Office (“EUIPO”) and Organisation for Economic Co-Operation and Development (“OECD”) recently published a Report on counterfeit pharmaceuticals based on global customs seizure data...more

Eversheds Sutherland (US) LLP

US-China Trade Agreement - Pharma impacts

President Trump has signed Phase I of a much anticipated multi-part trade agreement between the United States and China with provisions that will aid the branded pharmaceutical industry. One of the main goals of the agreement...more

Verrill

Is the New U.S.-China Agreement What Was Prescribed?

Verrill on

The trade relationship between China and the United States has been top of mind for businesses over the past year. In spring 2018, Chinese President Xi Jinping denied the U.S. Government's request to end subsidies for key...more

4 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide